Eli Lilly agreed to acquire Scorpion Therapeutics’ breast cancer treatment program for up to $2.5 billion in cash.

Shares of Eli Lilly & Co. LLY slipped 6.59% to $744.91 Tuesday, on what proved to be an all-around great trading session for ...

This was the stock's second consecutive day of gains.

DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating on January 21.Invest with Confidence: Follow ...

In a report released yesterday, Akash Tewari from Jefferies maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price ...

"Eli Lilly Cuts 4Q Sales Outlook After Sluggish Growth for Incretin Drugs," published at 10:06 a.m. ET, incorrectly said the outlook was around $400 below the low end of its last estimated range ...

Warren Buffett Owns 6 Dow Jones Stocks. Here's the Best of the Bunch for Income Investors to Buy Right Now.

iShares U.S. Pharmaceuticals ETF offers exposure to 42 companies that manufacture prescription or over-the-counter drugs or ...

For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com. Eli Lilly said it received Food and Drug Administration approval ...

Investors scored big wins last year as the S&P 500, the Nasdaq, and the Dow Jones Industrial Average all climbed ... Image ...

The Dow Jones Industrial Average rose on Tuesday as ... they had for obesity drugs may not materialize as hoped. Lilly shares, which were approaching a trillion-dollar market cap this summer ...

Eli Lilly has agreed to acquire Scorpion Therapeutics' breast cancer treatment program for up to $2.5 billion in cash. The drugmaker said Monday it is acquiring Scorpion and its STX-478 program ...